New diabetes clinical trial: An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

Published on: December 07, 2022 at 11:00AM
Conditions:   Chronic Kidney Disease;   Type 2 Diabetes
Interventions:   Drug: Finerenone (Kerendia, BAY94-8862);   Drug: Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Sponsor:   Bayer
Not yet recruiting
https://ift.tt/rC2P5wJ